CJC-1295 with DAC (5 mg vial)
Twice weekly subcutaneous protocol for growth hormone axis research.
CJC-1295 with DAC is a GHRH analog whose drug affinity complex binds albumin, stretching the half-life to about a week and lifting GH and IGF-1 for days per injection. The protocol below is twice-weekly subcutaneous, the cadence its pharmacokinetics were built for.
Quick answer: at the standard 5 mg + 0.5 mL reconstitution, a 1000 mcg dose of CJC-1295 with DAC draws 10 units (0.1 mL) on a U-100 insulin syringe, twice weekly subcutaneous.
Get CJC-1295 with DAC → code PEPDOSE
Protocol overview
Dosing & reconstitution
Frequency: Twice weekly subcutaneous
Typical duration: 8-12 weeks
Reconstitution: 5 mg vial + 0.5 mL bacteriostatic water = 10 mg/mL. Units below are for a U-100 insulin syringe at this concentration.
| Phase | Dose | Units per injection |
|---|---|---|
| Weeks 1-2 | 300 mcg | 3 units (0.03 mL) |
| Weeks 3-4 | 500 mcg | 5 units (0.05 mL) |
| Weeks 5-6 | 750 mcg | 7.5 units (0.075 mL) |
| Weeks 7-12 | 1000 mcg | 10 units (0.1 mL) |
Units = (dose ÷ concentration) × 100 on a U-100 syringe. Change the vial size or water volume and the calculator redoes all of this for you.
Track this protocol → Free account · log doses, rotate sites, never lose your history
CJC-1295 with DAC dosing schedule
From the phase 1 ascending-dose programme in healthy adults — two randomized, double-blind, placebo-controlled trials enrolling 65 subjects between them. This is dose-ranging pharmacology, not an efficacy protocol for any indication.
| Phase | Amount | Frequency | Notes |
|---|---|---|---|
| Ascending single doses | 1, 2, 4, 8, 15, 30 mcg/kg | Single subcutaneous dose | The ascending-dose arms of the phase 1 programme. |
| Higher single doses | 30, 60, 90 mcg/kg | Single subcutaneous dose | Produced 2–10 fold increases in mean plasma GH for 6+ days and 1.5–3 fold IGF-1 increases lasting 9–11 days. |
| Repeat dosing | Weekly or biweekly | 2–3 doses | The second trial in the programme tested multiple dosing. |
Study length: Single doses in the first trial; two or three weekly or biweekly doses in the second.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for CJC-1295 with DAC: 5 mg.
- Wipe the stoppers of both vials with an alcohol swab and let them dry.
- Draw the bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the peptide vial — never straight onto the powder.
- Swirl gently until the solution is clear. Do not shake; foaming and agitation damage peptides.
- Label the vial with the date and concentration, and refrigerate at 2–8 °C protected from light.
Worked example at the calculator defaults: 5 mg + 2 mL of bacteriostatic water = 2.5 mg/mL, so on a U-100 insulin syringe 1 unit = 25 mcg of CJC-1295 with DAC. Change either input and the calculator redoes this for you.
Storage and stability
Supplies math
Whatever amounts your research uses, the planning arithmetic is the same. The calculator runs all of this per compound.
Supplies by protocol length
Based on the maintenance dose above (1000 mcg, twice weekly subcutaneous) and a 5 mg vial reconstituted with 0.5 mL.
| Duration | Injections | Vials | Syringes | Bac water | Swabs |
|---|---|---|---|---|---|
| 8 weeks | 16 | 4 x 5 mg | 18 | 1 x 10 mL | 32 |
| 12 weeks | 24 | 5 x 5 mg | 27 | 1 x 10 mL | 48 |
| 16 weeks | 32 | 7 x 5 mg | 36 | 1 x 10 mL | 64 |
Syringe count includes ~10% spares. Swabs = 2 per injection (stopper + site). Vial count assumes the full maintenance dose for the entire duration.
Important notes
Practical considerations for consistency and safety.
- Use a new sterile insulin syringe for each injection and dispose in a proper sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and avoid lipohypertrophy.
- Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
- Administer on the same day each week for consistency. If a dose is missed, administer as soon as possible within a few days.
- The 5 mg vial size is standard for this compound. Reconstitute with 0.5 mL bacteriostatic water for a convenient concentration.
How CJC-1295 with DAC works
A GHRH analog carrying a Drug Affinity Complex — a maleimide group that binds covalently to serum albumin after injection. That bond is what stretches the half-life from minutes to days, and it is the entire difference between this and the no-DAC version.
Benefits & side effects
Potential benefits
- Long-acting GHRH analog with extended half-life
- Sustained GH elevation over days
- Less frequent dosing needed (twice weekly)
- Synergistic with GHRP peptides
Possible side effects
- Injection site reactions
- Facial flushing
- Water retention possible
- May elevate IGF-1 above desired range
This list reflects published literature and community reports. Individual responses vary. Not medical advice.
Bloodwork worth tracking
The community-standard practice is a baseline panel before starting, a recheck 8 to 12 weeks in, and another after time off. For CJC-1295 with DAC, the markers most worth watching:
IGF-1fasting glucoselipid panel
Typical time off: 4-8 wks
Lab panels are how a research protocol stays honest: numbers move before symptoms do. Interpretation belongs with a clinician. Not medical advice.
Lifestyle factors
None of the literature above was run on a background of poor sleep and no protein. These variables move outcomes more reliably than any compound on this site.
- Protein in the 1.6 to 2.2 g/kg range preserves lean mass through any body-composition phase.
- Resistance training 2 to 4 days per week plus 150+ minutes of weekly aerobic work reinforces whatever the protocol is doing.
- Sleep is the recovery window: 7 to 9 hours at consistent times.
- Hydration matters more than usual on compounds with GI or flushing effects: 2 to 3 liters daily.
- Track the variables that matter: weigh-ins, measurements, photos, and labs at sensible intervals.
Subcutaneous technique and practical notes
General best practice from clinical injection guidance — the same fundamentals nurses are taught, none of it specific to any compound.
Quick answers
How many syringe units is a 1000 mcg dose of CJC-1295 with DAC?
At the standard reconstitution of 5 mg with 0.5 mL bacteriostatic water (10 mg/mL), a 1000 mcg dose draws 10 units (0.1 mL) on a U-100 insulin syringe.
How do you reconstitute CJC-1295 with DAC?
Add 0.5 mL of bacteriostatic water to the 5 mg vial for 10 mg/mL. Inject the water slowly down the inside wall of the vial, swirl gently without shaking, and refrigerate at 2 to 8 °C after mixing.
How long does a 5 mg vial of CJC-1295 with DAC last?
About 5 maintenance doses of 1000 mcg, roughly 2.5 weeks at twice weekly subcutaneous.
Does CJC-1295 with DAC have human trial data?
Yes. The dosing on this page is anchored to published human research (Teichman SL et al., "Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults", J Clin Endocrinol Metab 2006).
How does CJC-1295 with DAC work?
A GHRH analog carrying a Drug Affinity Complex — a maleimide group that binds covalently to serum albumin after injection. That bond is what stretches the half-life from minutes to days, and it is the entire difference between this and the no-DAC version.
Sourcing CJC-1295 with DAC
Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.
CJC-1295 with DAC at Summit Research Supply → Grade a COA first
Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.
